Role of MeCP2 in neurological disorders: current status and future perspectives
2017; Future Medicine; Volume: 10; Issue: 1 Linguagem: Inglês
10.2217/epi-2017-0128
ISSN1750-1911
Autores Tópico(s)Moyamoya disease diagnosis and treatment
ResumoEpigenomicsVol. 10, No. 1 CommentaryRole of MeCP2 in neurological disorders: current status and future perspectivesJuan AusióJuan Ausió*Author for correspondence: E-mail Address: jausio@uvic.ca Department of Biochemistry & Microbiology, University of Victoria, Victoria, BC, V8W 3P6, CanadaPublished Online:27 Nov 2017https://doi.org/10.2217/epi-2017-0128AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: epigeneticsmethyl CpG binding protein 2neurodevelopmental and neurodegenerative disorderspost-translational modificationsRett syndromesubstance abuseReferences1 Fatemi M, Wade PA. MBD family proteins: reading the epigenetic code. J. Cell Sci. 119(Pt 15), 3033–3037 (2006).Crossref, Medline, CAS, Google Scholar2 Filarsky M, Zillner K, Araya I et al. The extended AT-hook is a novel RNA binding motif. RNA Biol. 12(8), 864–876 (2015).Crossref, Medline, Google Scholar3 Ausio J. MeCP2 and the enigmatic organization of brain chromatin. Implications for depression and cocaine addiction. Clin. Epigenetics 8, 58 (2016).Crossref, Medline, Google Scholar4 Ausió J, De Paz A, Esteller M. MeCP2: the long trip from a chromatin protein to neurological disorders. Trends Mol. Med. 20(9), 487–498 (2014).Crossref, Medline, CAS, Google Scholar5 Bellini E, Pavesi G, Barbiero I et al. MeCP2 post-translational modifications: a mechanism to control its involvement in synaptic plasticity and homeostasis? Front. Cell Neurosci. 8, 236 (2014).Crossref, Medline, Google Scholar6 Zoghbi HY. Rett syndrome and the ongoing legacy of close clinical observation. Cell 167(2), 293–297 (2016).Crossref, Medline, CAS, Google Scholar7 Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb. Perspect. Biol. 8(9), pii:a019505 (2016).Crossref, Medline, Google Scholar8 Neupane M, Clark AP, Landini S et al. MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy. Cancer Discov. 6(1), 45–58 (2015).Crossref, Medline, Google Scholar9 Collins AL, Levenson JM, Vilaythong AP et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 13(21), 2679–2689 (2004).Crossref, Medline, CAS, Google Scholar10 Martinez De Paz A, Vicente Sanchez-Mut J, Samitier-Marti M et al. Circadian cycle-dependent MeCP2 and brain chromatin changes. PLoS ONE 10(4), e0123693 (2015).Crossref, Medline, Google Scholar11 Thambirajah AA, Eubanks JH, Ausio J. MeCP2 post-translational regulation through PEST domains: two novel hypotheses: potential relevance and implications for Rett syndrome. Bioessays 31(5), 561–569 (2009).Crossref, Medline, CAS, Google Scholar12 Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 24, 677–736 (2001).Crossref, Medline, CAS, Google Scholar13 Gabel HW, Kinde B, Stroud H et al. Disruption of DNA-methylation-dependent long gene repression in Rett syndrome. Nature 522(7554), 89–93 (2015).Crossref, Medline, CAS, Google Scholar14 Van Esch H, Bauters M, Ignatius J et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am. J. Hum. Genet. 77(3), 442–453 (2005).Crossref, Medline, CAS, Google Scholar15 Suter B, Treadwell-Deering D, Zoghbi HY, Glaze DG, Neul JL. Brief report: MECP2 mutations in people without Rett syndrome. J. Autism Dev. Disord. 44(3), 703–711 (2014).Crossref, Medline, Google Scholar16 Sajan SA, Jhangiani SN, Muzny DM et al. Enrichment of mutations in chromatin regulators in people with Rett syndrome lacking mutations in MECP2. Genet. Med. 19(1), 13–19 (2017).Crossref, Medline, Google Scholar17 Curie A, Lesca G, Bussy G et al. Asperger syndrome and early-onset schizophrenia associated with a novel MECP2 deleterious missense variant. Psychiatr. Genet. 27(3), 105–109 (2017).Crossref, Medline, CAS, Google Scholar18 Eid A, Bihaqi SW, Renehan WE, Zawia NH. Developmental lead exposure and lifespan alterations in epigenetic regulators and their correspondence to biomarkers of Alzheimer's disease. Alzheimers Dement. (Amst) 2, 123–131 (2016).Crossref, Medline, Google Scholar19 Lyst MJ, Ekiert R, Ebert DH et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat. Neurosci. 16(7), 898–902 (2013).Crossref, Medline, CAS, Google Scholar20 Shah RR, Bird AP. MeCP2 mutations: progress towards understanding and treating Rett syndrome. Genome Med. 9(1), 17 (2017).Crossref, Medline, Google Scholar21 Lombardi LM, Zaghlula M, Sztainberg Y et al. An RNA interference screen identifies druggable regulators of MeCP2 stability. Sci. Transl. Med. 9(404), (2017).Crossref, Google Scholar22 Good KV, Martinez De Paz A, Tyagi M et al. Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding. Epigenetics doi: 10.1080/15592294.2017.1380760 (2017) (Epub ahead of print).Crossref, Medline, Google Scholar23 Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1(4), 287–299 (2002).Crossref, Medline, CAS, Google Scholar24 Young JI, Hong EP, Castle JC et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl Acad. Sci. USA 102(49), 17551–17558 (2005).Crossref, Medline, CAS, Google Scholar25 Maxwell SS, Pelka GJ, Tam PP, El-Osta A. Chromatin context and ncRNA highlight targets of MeCP2 in brain. RNA Biol. 10(11), 1741–1757 (2013).Crossref, Medline, CAS, Google Scholar26 Roignant JY, Soller M. m6A in mRNA: an ancient mechanism for fine-tuning gene expression. Trends Genet. 33(6), 380–390 (2017).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByDysregulation of transcription and human diseasesThe Cell Adhesion Molecule L1 Interacts with Methyl CpG Binding Protein 2 via Its Intracellular Domain24 March 2022 | International Journal of Molecular Sciences, Vol. 23, No. 7The Role of MeCP2 in Regulating Synaptic Plasticity in the Context of Stress and Depression21 February 2022 | Cells, Vol. 11, No. 4Spatiotemporal 22q11.21 Protein Network Implicates DGCR8-Dependent MicroRNA Biogenesis as a Risk for Late Fetal Cortical Development in Psychiatric Diseases31 May 2021 | Life, Vol. 11, No. 6MeCP2: latest insights fundamentally change our understanding of its interactions with chromatin and its functional attributes8 January 2021 | BioEssays, Vol. 43, No. 3MeCP2: The Genetic Driver of Rett Syndrome Epigenetics21 January 2021 | Frontiers in Genetics, Vol. 12Effect of Aging on the Behavior and Brain Expression of Genes Encoding Kaiso, BDNF, CREB, and STEP Proteins in Mice30 March 2021 | Advances in Gerontology, Vol. 11, No. 1Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease8 January 2021 | Biomolecules, Vol. 11, No. 1MECP2 mutation spectrum and its clinical characteristics in a Chinese cohort21 June 2020 | Clinical Genetics, Vol. 98, No. 3The cell adhesion molecule L1 interacts with nuclear proteins via its intracellular domain13 June 2020 | The FASEB Journal, Vol. 34, No. 8MeCP2 Promotes Colorectal Cancer Metastasis by Modulating ZEB1 Transcription23 March 2020 | Cancers, Vol. 12, No. 3Fetal alcohol spectrum disorder (FASD) affects the hippocampal levels of histone variant H2A.Z-2Biochemistry and Cell Biology, Vol. 97, No. 4Modeling rare pediatric neurogenetic disorders with IPSCsAIMS Cell and Tissue Engineering, Vol. 3, No. 1Spectrum of MECP2 mutations in Vietnamese patients with RETT syndrome6 August 2018 | BMC Medical Genetics, Vol. 19, No. 1 Vol. 10, No. 1 Follow us on social media for the latest updates Metrics Downloaded 181 times History Received 29 September 2017 Accepted 10 October 2017 Published online 27 November 2017 Published in print January 2018 Information© 2017 Future Medicine LtdKeywordsepigeneticsmethyl CpG binding protein 2neurodevelopmental and neurodegenerative disorderspost-translational modificationsRett syndromesubstance abuseAcknowledgementsThe author is thankful to HMO Reid and ME Freeman for carefully proofreading the manuscript.Financial & competing interests disclosure.Preparation of this manuscript was supported by the Canadian Institutes of Health Research (CIHR grant MOP -130417). The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)